SCHEDULE 13D: Mitesco Director Dr. Jordan Balencic Discloses 6.9% Beneficial Ownership Stake

Dr. Jordan Balencic, a director of Mitesco, Inc., has filed a Schedule 13D disclosing a 6.9% beneficial ownership stake in the company, primarily acquired through compensation for services.

Summary

• Dr. Jordan Balencic, a director of Mitesco, Inc., has filed a Schedule 13D, reporting beneficial ownership of 1,218,661 shares of Mitesco, Inc. Common Stock.
• This ownership represents 6.9% of the total Common Stock outstanding, which was 9,774,332 shares as of February 3, 2025.
• The beneficial ownership comprises 258,661 shares of Common Stock held directly and 2,400 shares of Series X Preferred Stock.
• Each share of Series X Preferred Stock entitles the holder to 400 votes per share on all matters submitted to a vote of common stockholders, contributing significantly to the total voting power.
• The shares were primarily acquired as compensation for director and non-director services rendered to the Issuer, including 2,400 Series X Preferred Stock on January 1, 2024, 10,132 Common Stock for accrued dividends between January 1, 2024, and January 15, 2025, 100,000 Common Stock on July 29, 2024, and 150,000 Common Stock on November 12, 2024.

Sentiment

Score: 6

Explanation: The document is a regulatory disclosure of beneficial ownership by a director. While the accumulation of shares by an insider can be seen as a positive signal of confidence, the filing itself does not contain performance metrics or strategic updates that would significantly shift sentiment. The stated possibility of future dispositions introduces a neutral element.

Positives

• A director, Dr. Jordan Balencic, has accumulated a significant beneficial ownership stake of 6.9% in Mitesco, Inc., indicating alignment of interests with shareholders.
• The acquisition of shares, including Series X Preferred Stock with enhanced voting rights, as compensation for services demonstrates management's commitment and belief in the company's value.

Risks

• The Reporting Person explicitly states the right to dispose of some or all of the beneficially owned shares periodically, which could potentially lead to selling pressure on the stock.

Future Outlook

The Reporting Person intends to evaluate their investments in Mitesco, Inc. on an ongoing basis and reserves the right to acquire additional shares if market conditions are favorable or dispose of existing shares through various means. There are no current plans for extraordinary corporate transactions, changes in the board or management, material changes in capitalization or dividend policy, or alterations to the company's business structure or governance documents.

Management Comments

• "The purpose of the Reporting Person's acquisition of the Series X Preferred Stock on January 1, 2024, was for investment purposes and to discharge obligations owed by the Issuer to the Reporting Person for services rendered."
• "The Reporting Person intends to evaluate on an ongoing basis the investments in the Issuer and their options with respect to such investments."
• "The Reporting Person may, from time to time and at any time, acquire additional shares of Common Stock for investment purposes if market conditions are favorable, in the open market, in privately negotiated transactions or otherwise."
• "The Reporting Person may also dispose of some or all of the shares of Common Stock that the Reporting Person beneficially owns, periodically, by public or private sale."

Industry Context

This Schedule 13D filing is a standard regulatory disclosure of a significant beneficial ownership stake by an insider. It does not provide information on broader industry trends or Mitesco, Inc.'s competitive positioning within the medical services sector.

Management Changes

Corporate Governance

Legal Proceedings

• The Reporting Person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the past five years.
• The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws during the past five years.

Related Party Transactions

• On January 1, 2024, the Issuer issued 2,400 shares of Series X Preferred Stock to Dr. Jordan Balencic as compensation for director services rendered.
• Between January 1, 2024, and January 15, 2025, the Issuer issued a total of 10,132 shares of Common Stock to Dr. Jordan Balencic for accrued dividends on the Series X Preferred Stock.
• On July 29, 2024, the Issuer issued 100,000 shares of Common Stock to Dr. Jordan Balencic as compensation for non-director services rendered.
• On November 12, 2024, the Issuer issued 150,000 shares of Common Stock to Dr. Jordan Balencic as compensation for non-director services rendered.

Stakeholder Impact

• Shareholders: Increased insider ownership by a director may be viewed positively as it aligns management interests with shareholders. However, the stated possibility of future share dispositions by the Reporting Person could introduce uncertainty regarding potential selling pressure.
• Management/Board: The director's significant stake and voting power (via Series X Preferred Stock) could influence corporate governance and strategic decisions.

Next Steps

• The Reporting Person will continue to evaluate their investment in Mitesco, Inc.
• The Reporting Person may acquire additional shares of Common Stock in the future if market conditions are favorable.
• The Reporting Person may dispose of some or all of their beneficially owned shares periodically.

Key Dates

Keywords

Mitesco Inc., Jordan Balencic, Schedule 13D, Beneficial Ownership, Common Stock, Series X Preferred Stock, Director Compensation, SEC Filing, Insider Ownership, Corporate Governance